LEPR and type 2 diabetes mellitus: Phase II type 2 diabetes fixed-dose CagriSema (n = 31) demonstrated 15.6 % loss at week 32 with progression of −8.5 % at week four, −13.0 % at week eight, −15.1 % at week 16, and -15.6 % at week 36, showing leptin/soluble leptin receptor ratio differentiation biomarker correlations.